August 22, 2007 presentation by Ron Levy for the Stanford School of Medicine Medcast lecture series.
Ron Levy, MD, professor of Medicine at Stanford, recounts his experiences moving his discovery from the lab to the clinical setting and discusses the future of this cancer treatment. Wendy Harpham, a participant in the early clinical trials of Rituxan, the first FDA-approved monoclonal antibody for cancer treatment that Levy developed, provides a patient's perspective.
Stanford University School of Medicine:
med.stanford.edu/
Stanford University Channel on RU-vid:
/ stanforduniversity
21 май 2008
